Robert Spiera
Hospital for Special Surgery, New York · Professor of Clinical Medicine, Weill Cornell Medical College · Weill Cornell Medical College, New York City, NY
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Robert Spiera as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03844061 · Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic SclerosisHospital for Special Surgery, New York · active not recruiting · Systemic Sclerosis · principal investigator
- Ph3NCT03398837 · Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic SclerosisCorbus Pharmaceuticals Inc. · terminated · Diffuse Cutaneous Systemic Sclerosis · principal investigator
- Ph2NCT02465437 · Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic SclerosisCorbus Pharmaceuticals Inc. · terminated · Diffuse Cutaneous Systemic Sclerosis · principal investigator
- Ph2NCT01670565 · Belimumab for the Treatment of Diffuse Cutaneous Systemic SclerosisHospital for Special Surgery, New York · completed · Systemic Sclerosis · principal investigator
- Ph2NCT01166139 · Nilotinib in the Treatment of Systemic SclerosisHospital for Special Surgery, New York · completed · Systemic Sclerosis · principal investigator
- Ph2NCT00555581 · Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisHospital for Special Surgery, New York · completed · Systemic Sclerosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:33 UTC. The ranking covers the 200 most relevant of 57 PubMed records, and a shared surname and initials can bring in a namesake. All 57 on PubMed
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis.N Engl J Med · 20102,080 citationsRCR 63.1
- Trial of Tocilizumab in Giant-Cell Arteritis.N Engl J Med · 2017987 citationsRCR 40.1
- Efficacy of remission-induction regimens for ANCA-associated vasculitis.N Engl J Med · 2013571 citationsRCR 20.0
- Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.J Clin Invest · 2015303 citationsRCR 10.2
- A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).Clin Exp Rheumatol · 2001258 citationsRCR 8.0
- A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.Arthritis Rheumatol · 2017250 citationsRCR 10.2
- Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.Ann Intern Med · 2005224 citationsRCR 6.0
- Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.Ann Rheum Dis · 2016202 citationsRCR 8.8
- Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.Ann Intern Med · 2007192 citationsRCR 5.4
- Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).Arthritis Rheum · 2005159 citationsRCR 4.9